Therapiekonzepte beim metastasierten Magenkarzinom

Die Chirurgie stellt die Behandlung der Wahl beim Magenkarzinom dar. Eine Systemtherapie prä- und/oder postoperativ kann die Heilungsraten verbessern. Für viele Patienten ist jedoch eine Heilung aufgrund des fortgeschrittenen Tumorstadiums nicht mehr möglich. In dieser palliativen Situation steht die Abwägung von Therapienutzen und Nebenwirkungen im Vordergrund; die Ziele sind Verlängerung der Lebenszeit und die Verbesserung der Lebensqualität.

• Literatur

• 1 Higuchi K, Tanabe S, Shimada K. et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer 2014; 50: 1437-1445
• 2 Janjigian YY, Riches JC, Ku GY. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. ASCO Meeting Abstr 2015; 33: 63
• 3 Janjigian YY, Werner D, Pauligk C. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662
• 4 Jeurnink SM, Steyerberg EW, van Hooft JE. et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 2010; 71: 490-499
• 5 Glimelius B, Ekström K, Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168
• 6 Findlay M, Cunningham D, Norman A. et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-616
• 7 Kim R, Nishimoto N, Inoue H. et al. An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J Infect Chemother 2000; 6: 222-228
• 8 Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010; 116: 2511-2518
• 9 Kaatsch P, Spix C, Katalinic A. et al. Krebs in Deutschland 2007/2008. Berlin: Robert Koch-Institut; 2012
• 10 Al-Batran SE, Hartmann JT, Hofheinz R. et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882-1887
• 11 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2012; 376: 687-697
• 12 Dank M, Zaluski J, Barone C. et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457
• 13 Kang YK, Kang WK, Shin DB. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673
• 14 Van Cutsem E, Kang Y, Chung H, Shen L. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. Proc ASCO 2009: Suppl-Abstr LBA4509.
• 15 Kang Y-K, Shah MA, Ohtsu A. et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol 2016; 34 (Suppl. 04) Abstr. 5
• 16 Satoh T, Xu RH, Chung HC. et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol 2014; 32: 2039-2049
• 17 Van Cutsem E, Moiseyenko VM, Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
• 18 Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009; 21: 381-385
• 19 Wagner AD, Unverzagt S, Grothe W. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (03) CD004064
• 20 Bouché O, Raoul JL, Bonnetain F. et al. Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328
• 21 Tebbutt NC, Norman A, Cunningham D. et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002; 13: 1568-1575
• 22 Fahlke J, Ridwelski K, Schmidt C. et al. A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer. Chemotherapy 2007; 53: 454-460
• 23 Thuss-Patience PC, Kretzschmar A, Repp M. et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23: 494-501
• 24 Cunningham D, Okines AFC, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010; 362: 858-859
• 25 Moehler M, Al-Batran SE, Andus T. et al. S3-Leitlinie „Magenkarzinom“ — Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. AWMF Registernummer 032-009OL. Z Gastroenterol 2011; 49: 461-531 http://www.awmf.org/leitlinien/detail/ll/032.009OL.html
• 26 Moehler M, Eimermacher A, Siebler J. et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs. 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128
• 27 Moehler M, Kanzler S, Geissler M. et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2009; 21: 71-77
• 28 Thuss-Patience PC, Kretzschmar A, Deist T. et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ASCO Meeting Abstr 2009; 27: 4540
• 29 Shin D, Lee S, Park S. et al. Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer. ASCO Meeting Abstr 2007; 25: 4580
• 30 Assersohn L, Brown G, Cunningham D. et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69
• 31 Rosati G, Bilancia D, Germano D. et al. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. Ann Oncol 2007; 18 Suppl 6: vi128-132
• 32 Ford HE, Marshall A, Bridgewater JA. et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86
• 33 Miranda MB, Hartmann JT, Al-Batran SE. et al. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol 2014; 140: 829-837
• 34 Fuchs CS, Tomasek J, Yong CJ. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
• 35 Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
• 36 Lordick F. Gastrointestinal cancer: Over the RAINBOW – renaissance in antiangiogenesis. Nat Rev Clin Oncol 2014; 12: 7-8
• 37 Hallissey MT, Allum WH, Roginski C. et al. Palliative surgery for gastric cancer. Cancer 1988; 62: 440-444
• 38 Hartgrink HH, Putter H, Klein Kranenbarg E. et al. Value of palliative resection in gastric cancer. Br J Surg 2002; 89: 1438-1443
• 39 Kulig P, Sierzega M, Kowalczyk T. et al. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol 2012; 38: 490-496
• 40 Meyer HJ, Hölscher AH, Lordick F. et al. Aktuelle S3-Leitlinie zur Chirurgie des Magenkarzinoms. Chirurg 2012; 83: 31-37
• 41 Lasithiotakis K, Antoniou SA, Antoniou GA. et al. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res 2014; 34: 2079-2085
• 42 Thrumurthy SG, Chaudry MA, Chau I. et al. Does surgery have a role in managing incurable gastric cancer?. Nat Rev Clin Oncol 2015; 12: 676-682
• 43 Mahar AL, Coburn NG, Singh S. et al. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2011; 15: 125-137
• 44 He MM, Zhang DS, Wang F. et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One 2013; 8: e83921
• 45 Samarasam I, Chandran BS, Sitaram V. et al. Palliative gastrectomy in Advanced gastric cancer: is it worthwhile?. ANZ J Surg 2006; 76: 60-63
• 46 Mariette C, Bruyère E, Messager M. et al. FREGAT Working Group. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?. Ann Surg Oncol 2013; 20: 1240-1249
• 47 Mahar AL, Coburn NG, Karanicolas PJ. et al. Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review. Gastric Cancer 2011; 15: 138-145
• 48 Yang HK, Tsujinaka T, Nakamura K. et al. Randomized controlled trial of comparing gastrectomy (Gx) plus chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a single non-curable factor: JCOG 0705/KGCA01 study (REGATTA). J Clin Oncol 2015; 33: No15 Supp
• 49 Al-Batran S-E, Hofheinz R, Homann N. et al. A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3. J Clin Oncol 2012; 30 (Suppl) Abstr. 4090